Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Ferrucci

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Cell|August 13, 1993
The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cellsF Grignani, P F Ferrucci, U Testa, et al.
Cancer Research|August 15, 1994
PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3U Testa, F Grignani, T Barberi, et al.
Blood|April 1, 1995
Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epitheliaL Flenghi, M Fagioli, L Tomassoni, et al.
Melanoma Research|March 10, 2015
Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II studyPier F Ferrucci, Ida Minchella, Massimo Mosconi, et al.
Oncogene|July 22, 1998
Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survivalM Fagioli, M Alcalay, L Tomassoni, et al.
British Journal of Haematology|November 6, 2007
High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomasPier F Ferrucci, Anna Vanazzi, Chiara M Grana, et al.
Leukemia & Lymphoma|June 14, 2003
ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphomaG Martinelli, P F Ferrucci, W Mingrone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2015
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumabS Valpione, C Martinoli, P Fava, et al.
Genes, Chromosomes & Cancer|June 13, 1998
In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genesM J Mozziconacci, C Liberatore, V Brunel, et al.
British Journal of Cancer|February 22, 2000
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicinC Corsini, M Ghielmini, P Mancuso, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Cell|August 13, 1993
The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cellsF Grignani, P F Ferrucci, U Testa, et al.
Cancer Research|August 15, 1994
PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3U Testa, F Grignani, T Barberi, et al.
Blood|April 1, 1995
Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epitheliaL Flenghi, M Fagioli, L Tomassoni, et al.
Melanoma Research|March 10, 2015
Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II studyPier F Ferrucci, Ida Minchella, Massimo Mosconi, et al.
Oncogene|July 22, 1998
Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survivalM Fagioli, M Alcalay, L Tomassoni, et al.
British Journal of Haematology|November 6, 2007
High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomasPier F Ferrucci, Anna Vanazzi, Chiara M Grana, et al.
Leukemia & Lymphoma|June 14, 2003
ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphomaG Martinelli, P F Ferrucci, W Mingrone, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2015
Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumabS Valpione, C Martinoli, P Fava, et al.
Genes, Chromosomes & Cancer|June 13, 1998
In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genesM J Mozziconacci, C Liberatore, V Brunel, et al.
British Journal of Cancer|February 22, 2000
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicinC Corsini, M Ghielmini, P Mancuso, et al.
Pageof 5